डाइसल्फिरम के इंटरैक्शन

Avoid using NUMBRINO in patients taking disulfiram. (कोकेन लेबल, दवाओं के इंटरैक्शन)

Alcohols, Disulfiram: Alcoholic beverages and preparations containing ethanol or propylene glycol should be avoided during tinidazole therapy and for 3 days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur. (टिनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

…reactions to dronabinol include lip swelling, hives, disseminated rash, oral lesions, skin burning, flushing, throat tightness [see Adverse Reactions ( 6.2 )] . with a history of a hypersensitivity reaction to alcohol. who are receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days [see Warning and Precautions ( 5.3 )] . (ड्रोनाबिनोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

CONTRAINDICATIONS Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. (डाइसल्फिरम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with TRACLEER is not recommended. (बोसेंटन लेबल, दवाओं के इंटरैक्शन)

CONTRAINDICATIONS Patients who are receiving or have recently received metronidazole, paraldehyde, alcohol, or alcohol-containing preparations, e.g., cough syrups, tonics and the like, should not be given disulfiram. (डाइसल्फिरम लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Moderate dual CYP3A4 and CYP2C9 inhibitors (fluconazole, amiodarone) or use of combined CYP3A4 and CYP2C9 inhibitors may increase exposure to macitentan: avoid co-administration with OPSUMIT ( 7.3 , 12.3 ). (मैसिटेंटन लेबल, दवाओं के इंटरैक्शन)

WARNING Disulfiram should never be administered to a patient when he is in a state of alcohol intoxication, or without his full knowledge. (डाइसल्फिरम लेबल, बॉक्स्ड चेतावनी)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

Disulfiram Decreases theophylline clearance by inhibiting hydroxylation and demethylation. (एमिनोफाइलिन लेबल, दवाओं के इंटरैक्शन)

Effect of TRIKAFTA on Other Drugs CYP2C9 Substrates Ivacaftor may inhibit CYP2C9; therefore, monitoring of the international normalized ratio (INR) during concomitant use of TRIKAFTA with warfarin is recommended. (एलेक्साकैफ्टर, टेज़ाकैफ्टर और आइवाकैफ्टर लेबल, दवाओं के इंटरैक्शन)

HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (एवानाफिल लेबल, दवाओं के इंटरैक्शन)

Amiodarone Amiodarone and its metabolite desethyl amiodarone, inhibitors of CYP2C9, and P- glycoprotein increased concentrations of the S(-)-enantiomer of carvedilol by at least 2 fold [see Clinical Pharmacology (12.5) ]. (कार्वेडिलोल लेबल, दवाओं के इंटरैक्शन)

Zafirlukast exposure is likely to be increased by other moderate and strong CYP2C9 inhibitors. (ज़ाफिरलुकास्ट लेबल, सावधानियां)

CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. (टॉरसेमाइड लेबल, दवाओं के इंटरैक्शन)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g. voriconazole) may enhance the exposure and toxicity of diclofenac whereas co- administration with CYP2C9 inducers (e.g. rifampin) may lead to compromised efficacy of diclofenac. (डाइक्लोफेनाक लेबल, दवाओं के इंटरैक्शन)

Co-administration of diclofenac with CYP2C9 inhibitors (e.g., voriconazole) may enhance the exposure and toxicity of diclofenac [see Clinical Pharmacology (12.3) ] whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of diclofenac. (डाइक्लोफेनाक और मिसोप्रोस्टोल लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

Disulfiram Decreases theophylline clearance by inhibiting hydroxylation and demethylation. (थियोफाइलिन लेबल, दवाओं के इंटरैक्शन)

…salicylates, monoamine oxidase inhibitors, non-selective beta-adrenergic-blocking agents, anabolic hormones (e.g., methandrostenolone), guanethidine, gymnema sylvestre, glucomannan, thioctic acid, and inhibitors of CYP2C9 (e.g., amiodarone, fluconazole, voriconazole, sulfinpyrazone) or in patients known to be poor metabolizers of CYP2C9 substrates, alcohol. (नेटेग्लिनाइड लेबल, दवाओं के इंटरैक्शन)

DISULFIRAM SHOULD BE USED WITH CAUTION IN THOSE PATIENTS RECEIVING PHENYTOIN AND ITS CONGENERS, SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

…(cimetidine), omeprazole Sulfonamides Sulfamethizole, sulfaphenazole, sulfadiazine, sulfamethoxazole-trimethoprim Other Acute alcohol intake, amiodarone, chloramphenicol, chlordiazepoxide, disulfiram, estrogen, fluvastatin, isoniazid, methylphenidate, phenothiazines, salicylates, ticlopidine, tolbutamide, trazodone, warfarin Drugs that may decrease phenytoin serum levels… (फॉस्फेनिटोइन लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

Thus concomitant usage of CYP2C9 inhibitors (such as amiodarone, fluconazole, and sulphaphenazole) may lead to abnormally high plasma levels of meloxicam due to reduced metabolic clearance [ see Use in Specific Populations ( 8.8 ); and Clinical Pharmacology ( 12.3 , 12.5 ) ]. (मेलोक्सिकैम लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

Fluconazole (strong CYP2C9 inhibitor): Increases systemic exposure of ramelteon; administer with caution. (रैमेल्टियॉन लेबल, दवाओं के इंटरैक्शन)

Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. (रोसुवास्टेटिन लेबल, दवाओं के इंटरैक्शन)

Strong CYP3A4 or CYP2C9 Inhibitors Patients with renal or hepatic impairment who are taking strong inhibitors of CYP3A4 and CYP2C9 may have a significant increase in exposure to VIMPAT. (लैकोसामाइड लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

Co-administration of celecoxib with drugs that are known to inhibit CYP2C9 (e.g., fluconazole) may enhance the exposure and toxicity of celecoxib whereas co-administration with CYP2C9 inducers (e.g., rifampin) may lead to compromised efficacy of celecoxib. (सेलेकॉक्सिब लेबल, दवाओं के इंटरैक्शन)

It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping disulfiram, since disulfiram may prolong prothrombin time. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

Patients taking isoniazid when disulfiram is given should be observed for the appearance of unsteady gait or marked changes in mental status, the disulfiram should be discontinued if such signs appear. (डाइसल्फिरम लेबल, दवाओं के इंटरैक्शन)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (एमिट्रिप्टिलीन लेबल, दवाओं के इंटरैक्शन)

Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). (ओमेप्राज़ोल लेबल, दवाओं के इंटरैक्शन)

Other Clinical Impact: There have been clinical reports of interactions with other drugs metabolized via the cytochrome P450 system (e.g., cyclosporine, disulfiram). (ओमेप्राज़ोल और सोडियम बाइकार्बोनेट लेबल, दवाओं के इंटरैक्शन)

Alcohol: Exceptional cases have been reported of a disulfiram-like reaction to alcohol, characterized by flushing, rash, peripheral edema, nausea and headache. (कीटोकोनाज़ोल लेबल, दवाओं के इंटरैक्शन)

However, at high concentrations in vitro , clopidogrel inhibits CYP2C9. (क्लोपिडोग्रेल लेबल, दवाओं के इंटरैक्शन)

Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes. (टर्बिनाफिन लेबल, दवाओं के इंटरैक्शन)

Toremifene is a weak inhibitor of CYP2C9. (टोरेमिफेन लेबल, दवाओं के इंटरैक्शन)

Disulfiram/metronidazole KALETRA oral solution contains ethanol, which can produce disulfiram-like reactions when co-administered with disulfiram or other drugs that produce this reaction (e.g., metronidazole). (लोपिनाविर और रिटोनाविर लेबल, दवाओं के इंटरैक्शन)

The interaction is a consequence of blocking hepatic metabolism of vardenafil by ritonavir, a HIV protease inhibitor and a highly strong CYP3A4 inhibitor, which also inhibits CYP2C9. (वार्डेनाफिल लेबल, दवाओं के इंटरैक्शन)

CYP2C9 Venlafaxine did not inhibit CYP2C9 in vitro . (वेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)

Additionally, no disulfiram-like reactions were reported in a study conducted in 22 healthy volunteers administered cefotaxime and ethanol. (सेफोटैक्सिम लेबल, दवाओं के इंटरैक्शन)

The pharmacokinetics of acamprosate are not affected by alcohol, diazepam, or disulfiram, and clinically important interactions between naltrexone and acamprosate were not observed [ see Clinical Pharmacology ( 12.3 ) ]. (एकैम्प्रोसेट लेबल, दवाओं के इंटरैक्शन)